Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V A Miller

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2000
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivoF M Sirotnak, H G Wendel, W G Bornmann, et al.
American Journal of Clinical Oncology|August 1, 1995
Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapyV A Miller, J R Rigas, K M Pisters, et al.
Cancer Research|June 15, 1996
Metabolic phenotypes of retinoic acid and the risk of lung cancerJ R Rigas, V A Miller, Z F Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancerV A Miller, K K Ng, S C Grant, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancerV A Miller, J R Rigas, W P Tong, et al.
American Journal of Clinical Oncology|October 22, 1998
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancerH L Kindler, M G Kris, I E Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2014
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myelomaJ P Sharman, J Chmielecki, D Morosini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550)S L Soignet, V A Miller, D G Pfister, et al.
Gynecologic Oncology|June 25, 2013
Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapiesJ S Ross, S M Ali, K Wang, et al.
Blood|June 1, 1995
9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemiaW H Miller, A Jakubowski, W P Tong, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2000
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivoF M Sirotnak, H G Wendel, W G Bornmann, et al.
American Journal of Clinical Oncology|August 1, 1995
Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapyV A Miller, J R Rigas, K M Pisters, et al.
Cancer Research|June 15, 1996
Metabolic phenotypes of retinoic acid and the risk of lung cancerJ R Rigas, V A Miller, Z F Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancerV A Miller, K K Ng, S C Grant, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancerV A Miller, J R Rigas, W P Tong, et al.
American Journal of Clinical Oncology|October 22, 1998
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancerH L Kindler, M G Kris, I E Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2014
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myelomaJ P Sharman, J Chmielecki, D Morosini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550)S L Soignet, V A Miller, D G Pfister, et al.
Gynecologic Oncology|June 25, 2013
Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapiesJ S Ross, S M Ali, K Wang, et al.
Blood|June 1, 1995
9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemiaW H Miller, A Jakubowski, W P Tong, et al.
Pageof 6